期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗CD33单抗联合化疗药物治疗复发或难治性急性髓系白血病的疗效观察 被引量：6

原文传递
导出
摘要 目的评价抗CD33单克隆抗体(GO)联合化疗药物对复发(或难治性)急性髓系白血病(AML)的疗效和安全性。方法应用GO联合化疗药物治疗16例复发或难治性AML患者。治疗方法:GO 9 mg/m2,第1天;联合FLAG、HAA、CAG、合用地西他滨等化疗方案。在治疗过程中同时应用前列腺素E以及保肝药物保护性治疗。结果 16例中,难治性AML11例,复发性AML5例,白血病细胞CD33表达中位数为93.9%。GO联合化疗1个疗程后复查骨髓象,达完全缓解(CR)7例,部分缓解(PR)3例,CR率为43.8%,PR率为18.8%,总有效率为62.6%。随访截至2010年3月1日,中位无复发生存时间为3.5(1.1～70)个月,中位总生存时间9(3～77)个月。在化疗过程中5例出现一过性高胆红素血症及转氨酶升高,化疗结束后有3例在异基因造血干细胞移植过程中出现肝静脉闭塞综合征,1例经抗凝、溶栓、保肝及对症支持治疗后症状得到控制,2例死亡。结论 GO联合化疗治疗复发、难治性AML患者可获得较高的CR率,为部分患者行异基因造血干细胞移植提供了契机,可作为伴有CD33高表达复发或难治性AML患者一种较为有效的治疗方法。
作者 王谦 仇惠英 吴德沛 孙爱宁 金正明 苗瞄 唐晓文 傅铮铮 韩悦 何广胜
机构地区 苏州大学附属第一医院江苏省血液研究所卫生部血栓与止血重点实验室
出处 《苏州大学学报（医学版）》 CAS 北大核心 2011年第2期317-320,共4页 Suzhou University Journal of Medical Science
关键词 抗CD33单克隆抗体 难治 复发 急性髓系白血病
分类号 R733.710.5 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Kimby E, Nygren P, Glimelius B, et al. A systematic overview of chemotherapy effects in acute myeloid leukaemia [ J]. Acta Oncol,2001,40(2/3 ) :231 - 252.
  • 2Montillo M, Ricci F,Tedeschi A, et al. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeliod leukemia [ J ]. Leuk Res, 2009, 33 ( 8 ) : 1072 - 1078.
  • 3Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia [ J ]. Blood, 2005,106 (4) : 1154 - 1163.
  • 4Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leuke- mia:a prospective study of the alfa group [ J ]. Leukemia, 2007,21 ( 1 ) :66 -71.
  • 5Burnett AK. The treatment of AML : current status and novel approaches [ J ]. Hematology, 2005,10 ( 1 ) : 50 - 53.
  • 6Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin( Mylotarg) in patients with CD33-positive acute myeloid leuke- mia in first recurrence [ J 1- Cancer, 2005,104 ( 7 ) : 1442 - 1452.
  • 7Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozo- gamicin,fludarabine, cytarabine and cyclosporine combina- tion regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia [ J ]. Leuk Res, 2003,27 (10) :893 - 897.
  • 8Alvarado Y,Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg,idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia[J]. Cancer Chemother Pharmacol,2003,51 (1): 87 - 90.
  • 9Chevallier P, Delaunay J,Turlure P, et al. Long-term dis- ease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia [ J ]. J Clin Oncol,2008,26(32) :5192-5197.
  • 10Lowenberg B, Beck J, Graux C, et al. Gemtuzumab ozo- gamicin as postremission treatment in AML at 60 years of age or more: resuhs of a multicenter phase 3 study [ J ]. Blood,2010,115 (13) :2586 - 2591.

二级参考文献2

  • 1Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation [ J ].Blood, 2000, 95: 3702 - 3709.
  • 2Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendation from a workshop at the 2001 tandem Meeting of the International Bone Marrow Transplant Regis

共引文献1

同被引文献78

  • 1Bobby Chawla, Abraham Sebastian Kanate, Salman Osman, et al. Clofarabine In Combination with Cyelophosphamide for Treatment of Relapsed/Refractory Acute Leukemia In Adult Patients [J]. Blood, 2010,116:4367-4372.
  • 2William Blum, Rebecca B. Klisovic, Heiko Becker, et al. Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias[J]. Journal of Clinical Oncology,2010,28:4919-4925.
  • 3Guoqing Wei, Delong Liu. Meta-Analysis of CAG (cytarabine, aclarubicin, G-CSF) Regimen for the Treatment of 580 Patients with Acute Leukemia In China and Japan[J]. Blood,2010,116:1064.
  • 4Joanne Filicko-O'Hara, Bijoyesh Mookerjee, Onder Alpdogan, et al. Phase II Study of Bortezomib, Mitoxantrone and Etoposide In Relapsed/Refractory Acute Leukemias[J]. Blood,2010,116:2192.
  • 5KUmm arer t of multiple myeloma[j]S'.Rajkumar SV. ThalidomidE eur J Cancer,2006,42(11): 1612-162an 2d lenalidomide in ]he treat-.
  • 6Richardson PG, Mitslades C, Hidesxima T, et al. Lenalidomide in multiple myeloma[J]. Expert Rev Anticancer,2006,6(8): 1165-1173.
  • 7Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies [J]. Expert Opin Pharma- cother,2007,8(4):497 -509.
  • 8Christine I. Chen, MD, Harminder Paul, Pantoja Mariela, et al. A Phase II Study of Lenalidomide in Previously Untreated, Symptom- atic Chronic Lymphocytic Leukemia (CLL)[J]. Blood,2007,110:2042.
  • 9Marie-Luise Huetter, MD, Walter Fiedler, MD, Andrea Kuendgen, MD, et al. Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia [J]. Blood,2010,116:3279.
  • 10Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, et al. Phase I Study of Lenalidomide in Acute Leukemia: Remi- ssions in Post-Allogeneic Relapse of Acute Myeloid Leukemia [J]. Blood,2009,114:84.

引证文献6

二级引证文献25

苏州大学学报（医学版）
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部